Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02897349
Other study ID # 1218.102
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date September 30, 2016
Est. completion date January 18, 2019

Study information

Verified date March 2020
Source Boehringer Ingelheim
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate the efficacy and safety of linagliptin compared to placebo when added on to insulin therapy alone or in combination with metformin in Chinese patients with type 2 diabetes mellitus with insufficient glycaemic control


Recruitment information / eligibility

Status Completed
Enrollment 206
Est. completion date January 18, 2019
Est. primary completion date January 11, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion criteria:

- Diagnosis of type 2 diabetes mellitus prior to informed consent.

- Chinese male or female patients who are pre-treated with insulin alone or in combination with metformin:

- With maximum insulin dose of <= 1 unit/kg/day. Acceptable basal insulins could be insulin glargin, insulin detemir or NPH (neutral protamin hagedorn) insulin with duration of action up to 24 h; acceptable pre-mixed insulins could be preparations with 25/75 or 30/70 ratio, with once or twice daily posology only. The total insulin dose should not be changed by more than 10% of the baseline value within the 12 weeks prior to randomisation (Visit 3). Both human insulin & insulin analogue are accepted.

- If the patient is taking metformin, stable dose (at least 1500 mg daily) must be maintained for at least 12 weeks without dose adjustments prior to randomisation (Visit 3).

- HbA1c fulfills the following criteria: >= 7.5 % to <= 10.0 % at Visit 1.

- Age >= 18 years at Visit 1.

- BMI <= 45 kg/m2 (Body Mass Index) at Visit 1.

- Women of childbearing potential must be ready and able to use highly effective methods of birth control per ICH (International Conference on Harmonisation) M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria is provided in the patient information.

- A woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile.

- Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy.

- Signed and dated written informed consent by date of Visit 1 in accordance with ICH-GCP (Good Clinical Practice) and local legislation

Exclusion criteria:

- Uncontrolled hyperglycaemic with a glucose level >240 mg/dl (>13.3 mmol/L) after an overnight fast during placebo run-in and confirmed by a second measurement (not on the same day).

- Any other antidiabetic drug within 3 months prior to informed consent except those defined as background treatment via inclusion criterion 2.

- Acute coronary syndrome (non-STEMI (ST Segment Elevation Myocardial Infarction), STEMI and unstable angina pectoris), stroke or TIA (Transient ischemic attack) within 3 months prior to informed consent.

- Indication of liver disease, defined by serum levels of either ALT (Alanine aminotransferase) (SGPT (serum glutamic pyruvate transaminase )), AST (Aspartate aminotransferase) (SGOT (serum glutamic-oxaloacetic transaminase)), or alkaline phosphatase above 3 × upper limit of normal (ULN (upper limit of normal)) as determined during screening and/or run-in phase.

- Any contraindications to metformin according to the local label for those patients that enter the study with metformin therapy as provided in ISF (Investigator Site File).

- Bariatric surgery within the past two years and other gastrointestinal surgeries that induce chronic malabsorption.

- Medical history of cancer (except for basal cell carcinoma) and/or treatment for cancer within the last 5 years.

- Blood dyscrasias or any disorders causing hemolysis or unstable Red Blood Cell (e.g. malaria, babesiosis, haemolytic anemia).

- Known hypersensitivity or allergy to the investigational product or its recipients.

- Treatment with anti-obesity drugs 3 months prior to informed consent or any other treatment at the time of screening (i.e. surgery, aggressive diet regimen, etc.) leading to unstable body weight.

- Current treatment with systemic steroids at time of informed consent or change in dosage of thyroid hormones within 6 weeks prior to informed consent or any other uncontrolled endocrine disorder except T2DM (Type 2 diabetes mellitus).

- Women who are pregnant, nursing, or who plan to become pregnant while in the trial.

- Alcohol or drug abuse within the 3 months prior to informed consent that would interfere with trial participation or any ongoing condition leading to a decreased compliance to study procedures or study drug intake in the opinion of the investigator.

- Participation in another trial with an investigational drug within 2 months prior to informed consent or previous enrolment in this trial.

- Any other clinical condition that would jeopardize patient's safety while participating in this clinical trial in the opinion of the investigator.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
placebo

linagliptin

background therapy
insulin with or without metformin

Locations

Country Name City State
China Beijing Tongren Hospital Beijing
China China-Japan Friendship Hospital Beijing
China The General Hospital of Chinese People's Armed Police Forces Beijing
China First Hospital of Jilin University Changchun
China No.900 Hospital of PLA Joint Logistics Support Force Fuzhou
China Third Affiliated Hospital of Guangzhou Medical University Guangzhou
China The Affiliated Hospital of Guizhou Medical University Guiyang
China The Affiliated Hospital of Hangzhou Normal University Hangzhou
China General Hospital of Jinan Military Area Jinan
China Nanjing First Hospital Nanjing
China The affiliated hospital of medicalcollege qingdao university Qingdao
China Centre Hospital of Putuo District, Shanghai Shanghai
China Shanghai Tenth People's Hospital Shanghai
China Yangpu Hospital, Tongji University Shanghai
China Second Hospital Affiliated to Shantou Medical University Shantou
China Shengjing Hospital of China Medical University Shengyang
China Siping Central People's Hospital Siping
China The First Affiliated Hospital of Soochow University Suzhou
China Nankai University Affiliated Hospital Tianjin
China The 2nd Hospital of Tianjin Medical University Tianjin
China Tianjin Medical University General Hospital Tianjin
China Renmin Hospital of Wuhan University Wuhan
China First Affiliated Hospital of Xiamen University Xiamen
China the first people hospital of Yue Yang Yueyang
China Affiliated Hospital of Jiangsu University Zhenjiang

Sponsors (2)

Lead Sponsor Collaborator
Boehringer Ingelheim Eli Lilly and Company

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) After 24 Weeks of Treatment Percentage change from baseline, that is, [[(HbA1c after 24 weeks of treatment) - (HbA1c at baseline)] / (HbA1c at baseline)] *100%, where baseline refers to the last observation prior to the start of randomised study drug, including the observation prior to the placebo run-in. Baseline and week 24
Secondary Change From Baseline in Fasting Plasma Glucose (FPG) After 24 Weeks of Treatment Change from baseline in Fasting plasma glucose (FPG) after 24 weeks of treatment. Baseline and week 24
Secondary Change From Baseline in 2-hour (2-h) Postprandial Plasma Glucose (PPG) After 24 Weeks of Treatment Change from baseline in 2-hour (2-h) postprandial plasma glucose (PPG) after 24 weeks of treatment. Baseline and week 24
Secondary Percentage of Participants With HbA1c on Treatment <7.0 Percentage (%) After 24 Weeks of Treatment Percentage of participants with HbA1c on treatment <7.0 percentage (%) after 24 weeks of treatment. Participants with baseline HbA1c <7.0% were excluded from the analysis. 24 weeks
Secondary Percentage of Participants With HbA1c on Treatment < 6.5% After 24 Weeks of Treatment Percentage of participants with HbA1c on treatment < 6.5% after 24 weeks of treatment. Participants with baseline HbA1c <6.5% were excluded from the analysis. 24 weeks
Secondary Percentage of Participants With HbA1c Lowering by at Least 0.5% After 24 Weeks of Treatment Percentage of participants with HbA1c lowering by at least 0.5% after 24 weeks of treatment. 24 weeks
Secondary Percentage of Participants With Any Investigator-defined Hypoglycaemic Adverse Event (AE) With Plasma Glucose (PG) =70 mg/dL Incidence of investigator-reported hypoglycaemic events confirmed by a measured blood glucose =70 mg/dL (=3.9 Millimoles Per Litre (mmol/L)). Severe hypoglycaemic AE = hypoglycaemic event requiring the assistance of another person to actively administer carbohydrate, glucagon or other resuscitative actions. 24 weeks
Secondary Percentage of Participants With Any Severe Hypoglycaemic AE Incidence of severe hypoglycaemic events (requiring active assistance by another person, or fatal). Severe hypoglycaemic AE = hypoglycaemic event requiring the assistance of another person to actively administer carbohydrate, glucagon or other resuscitative actions. 24 weeks
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05666479 - CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
Completed NCT05647083 - The Effect of Massage on Diabetic Parameters N/A
Active, not recruiting NCT05661799 - Persistence of Physical Activity in People With Type 2 Diabetes Over Time. N/A
Completed NCT03686722 - Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin Phase 1
Completed NCT02836704 - Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose) Phase 4
Completed NCT01819129 - Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes Phase 3
Completed NCT04562714 - Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy N/A
Completed NCT02009488 - Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM) Phase 1
Completed NCT05896319 - Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2 N/A
Recruiting NCT05598203 - Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes N/A
Completed NCT05046873 - A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People Phase 1
Terminated NCT04090242 - Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes N/A
Completed NCT04030091 - Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus Phase 4
Completed NCT03604224 - A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
Completed NCT03620357 - Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D) N/A
Completed NCT01696266 - An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
Completed NCT03620890 - Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy Phase 4
Withdrawn NCT05473286 - A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
Not yet recruiting NCT05029804 - Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes N/A
Completed NCT04531631 - Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes Phase 2

External Links